Arbolishvili GN, Mareev VY Institute of Clinical Cardiology, Moscow, Russia

Similar documents
Online Appendix (JACC )

Heart Rate Variability in Heart Failure and Sudden Death

Efficacy of beta-blockers in heart failure patients with atrial fibrillation: An individual patient data meta-analysis

HRV and Risk Stratification: Post-MI. Phyllis K. Stein, Ph.D. Washington University School of Medicine St. Louis, MO

New evidences in heart failure: the GISSI-HF trial. Aldo P Maggioni, MD ANMCO Research Center Firenze, Italy

Supplemental Material

Heart Failure. Guillaume Jondeau Hôpital Bichat, Paris, France

Prognostic Value of Cardiopulmonary Exercise Testing in Patients with Atrial Fibrillation

Randomized Trial to Optimize the Dose and Efficacy of Beta-Blocker in Systolic Heart Failure: Japanese Chronic Heart Failure (J-CHF) Study

Rita Calé, Miguel Mendes, António Ferreira, João Brito, Pedro Sousa, Pedro Carmo, Francisco Costa, Pedro Adragão, João Calqueiro, José Aniceto Silva.

Effects of heart rate reduction with ivabradine on left ventricular remodeling and function:

Take-home Messages from Recent Heart Failure Trials: Heart Rate as a Target

Treatment of Atrial Fibrillation in Heart Failure

Effects of heart rate reduction with ivabradine on left ventricular remodeling and function:

Clinical Outcome in Patients with Aortic Stenosis

Autonomic nervous system, inflammation and preclinical carotid atherosclerosis in depressed subjects with coronary risk factors

Rest and Exercise Echocardiography in Hypertrophic Cardiomyopathy: Determinants of Exercise Peak Gradient and Predictors of Outcome

Do All Patients With An ICD Indication Need A BiV Pacing Device?

HFpEF, Mito or Realidad?

SCD-HeFT: The Sudden Cardiac Death in Heart Failure Trial

Effect on sudden death

The Role of Ventricular Electrical Delay to Predict Left Ventricular Remodeling With Cardiac Resynchronization Therapy

Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes

Position Statement on ALDOSTERONE ANTAGONIST THERAPY IN CHRONIC HEART FAILURE

Primary prevention of SCD with the ICD in Nonischemic Cardiomyopathy

It has been shown from meta-analysis of randomized clinical trials that patients with a pre-crt QRS duration (QRSD) >150 ms benefit

The benefit of treatment with -blockers in heart failure is

ST2 in Heart Failure. ST2 as a Cardiovascular Biomarker. Competitive Model of ST2/IL-33 Signaling. ST2 and IL-33: Cardioprotective

Heart Rate and Cardiac Allograft Vasculopathy in Heart Transplant Recipients

DECLARATION OF CONFLICT OF INTEREST

Journal of the American College of Cardiology Vol. 35, No. 3, by the American College of Cardiology ISSN /00/$20.

Aldosterone Antagonism in Heart Failure: Now for all Patients?

Resynchronization/Defibrillation

NCAP NATIONAL CARDIAC AUDIT PROGR AMME NATIONAL HEART FAILURE AUDIT 2016/17 SUMMARY REPORT

Heart Failure Medical and Surgical Treatment

Χριστίνα Χρυσοχόου Καρδιολόγος Επι,Α Καρδιολογική Κλινική Πανεπιστηίου Αθηνών, ΙΓΝΑ

Treatment Of Preserved Cardiac Function Heart Failure with an Aldosterone antagonist (TOPCAT) AHA Nov 18, 2014 Update on Randomized Trials

12 th Annual Biomarkers in Heart Failure and Acute Coronary Syndromes: Diagnosis, Treatment and Devices. Heart Rate as a Cardiovascular Biomarker

Heart-rate Variability Christoph Guger,

Prognostic Value of Intramyocardial Hemorrhage Detected by Cardiac Magnetic Resonance Imaging in Acute Reperfused ST-Elevation Myocardial Infarction

The National Heart Failure Audit 2010/2011

Abstract ESC Pisa

Noninvasive Predictors of Sudden Cardiac Death

Digoxin And Mortality in Patients With Atrial Fibrillation With and Without Heart Failure: Does Serum Digoxin Concentration Matter?

Prognostic Value of Left Ventricular Dyssynchrony by Phase Analysis of Gated SPECT in Patients Undergoing Myocardial Perfusion Imaging

GALECTIN-3 PREDICTS LONG TERM CARDIOVASCULAR DEATH IN HIGH-RISK CORONARY ARTERY DISEASE PATIENTS

Catheter Ablation of Atrial Fibrillation Strategy and Outcome Predictors Shih-Ann Chen MD

egfr > 50 (n = 13,916)

The mortality of high-risk patients surviving myocardial

The Hearth Rate modulators. How to optimise treatment

Updates in Congestive Heart Failure

Pharmacological Treatment for Chronic Heart Failure. Dr Elaine Chau HK Sanatorium & Hospital, Hong Kong 3 August 2014

eplerenone 25, 50mg film-coated tablets (Inspra ) SMC No. (793/12) Pfizer Ltd

Investor Conference Call

The Effect of Vagus Nerve Stimulation in Heart Failure: Primary Results of the INcrease Of VAgal TonE in chronic Heart Failure (INOVATE-HF) Trial

Transient Atrial Fibrillation and Risk of Stroke after Acute Myocardial Infarction

In the 2002 American College of Cardiology/American

Disclosures. Overview. Goal statement. Advances in Chronic Heart Failure Management 5/22/17

The Author(s) This article is published with open access by ASEAN Federation of Cardiology

Conflict of interest statement

Intravenous Inotropic Support an Overview

Measuring autonomic activity Heart rate variability Centre for Doctoral Training in Healthcare Innovation

The Role of ICD Therapy in Cardiac Resynchronization

Arrhythmias and Heart Failure Dr Chris Lang Consultant Cardiologist and Electrophysiologist Royal Infirmary of Edinburgh

HEART FAILURE: PHARMACOTHERAPY UPDATE

ICD. Guidelines and Critical Review of Trials. Win K. Shen, MD Professor of Medicine Mayo Clinic College of Medicine Mayo Clinic Arizona Torino 2011

Hospital and 1-year outcome after acute myocardial infarction in patients with diabetes mellitus and hypertension

Reducing Hospital Readmissions and Increasing Time to Hospital Readmission in Blacks with Heart Failure

Optimal blockade of the Renin- Angiotensin-Aldosterone. in chronic heart failure

Cardiovascular Health Practice Guideline Outpatient Management of Coronary Artery Disease 2003

National Horizon Scanning Centre. Irbesartan (Aprovel) for heart failure with preserved systolic function. August 2008

β 1 Adrenergic Receptor Polymorphism-Dependent Differences

Heart Failure. Jay Shavadia

Supplementary Online Content

The implantable cardioverter defibrillator is not enough: Ventricular Tachycardia Catheter Ablation in Patients with Structural Heart Disease

ESTECK Status Report [Abridged]

Therapeutic Targets and Interventions

Saudi Arabia February Pr Michel KOMAJDA. Université Pierre et Marie Curie Hospital Pitié Salpétrière

Dobutamine-induced increase in heart rate is blunted by ivabradine treatment in patients with acutely decompensated heart failure

How atrial fibrillation should be treated in the heart failure patient?

Heart rate lowering treatment in chronic heart failure

Management of new-onset AF: Initial rate control treatment

Central pressures and prediction of cardiovascular events in erectile dysfunction patients

PROGNOSTIC VALUE OF OSTEOPROTEGERIN IN CHRONIC HEART FAILURE: THE GISSI-HF TRIAL

Copeptin in heart failure: Associations with clinical characteristics and prognosis

Heart Failure Treatments

Medical management of LV aneurysm and subsequent cardiac remodeling: is it enough? J. Parissis Attikon University Hospital Athens, Greece

Vest Prevention of Early Sudden Death Trial (VEST)

What s new in 2016 Guidelines of the European Society of Cardiology? HEART FAILURE. Marc Ferrini (Lyon Fr)

A patient with decompensated HF

Relationship between body mass index, coronary disease extension and clinical outcomes in patients with acute coronary syndrome

Biomarkers in the Assessment of Congestive Heart Failure

Impact of Nicorandil on Renal Function in Patients With Acute Heart Failure and Pre-Existing Renal Dysfunction

Echocardiographic Correlates of Pulmonary Artery Systolic Pressure

Desmin expression in cardiomyocytes - a good predictor of development of chronic heart failure.

Predictors of cardiac allograft vasculopathy in pediatric heart transplant recipients

Atrial Fibrillation and Heart Failure: A Cause or a Consequence

Antialdosterone treatment in heart failure

Neprilysin Inhibitor (Entresto ) Prior Authorization and Quantity Limit Program Summary

Disclosures. Advances in Chronic Heart Failure Management 6/12/2017. Van N Selby, MD UCSF Advanced Heart Failure Program June 19, 2017

Transcription:

THE VALUE OF 24 H HEART RATE VARIABILITY IN PREDICTING THE MODE OF DEATH IN PATIENTS WITH HEART FAILURE AND SYSTOLIC DYSFUNCTION IN BETA-BLOCKING BLOCKING ERA Arbolishvili GN, Mareev VY Institute of Clinical Cardiology, Moscow, Russia ISHNE Heart Failure World-Wide Wide Internet Symposium,, 2006

Heart Rate Variability (HRV) LF 0,04-0,15 Hz HF 0,15-0,40 Hz SDNN Sympathetic/vagal modulation Parasympathetic modulation

Objectives: To assess the relationship between parameters of HRV and traditional clinical markers of unfavorable prognosis with total mortality and mode of death in pts with heart failure and LV dysfunction in beta-blocking blocking era.

Inclusion criteria Symptomatic heart failure (NYHA II-IV IV) Sinus rhythm Left ventricle systolic dysfunction (LVEF 40%) Stable clinical condition

Exclusion criteria non-sinus rhythm myocardial infarction (< < 3 months) diabetes mellitus SA and AV-block renal failure severe non-cardiac diseases (with poor prognosis)

Study design Prospective observational study

End points Primary endpoint all-cause mortality Secondary endpoints pump failure death (PFD) sudden death (SD)

Statistical analysis (stepwise regression analysis) Clinical variables HRV variables Univariable model p<0.1 Multivariable model p<0.05 Univariable model p<0.1 Multivariable model p<0.05 Final prognostic model based on forward stepwise Cox proportional hazard regression p<0.05 INDEPENDENT PREDICTORS

Baseline patients clinical characteristics Age, yrs Gender (m/f) Etiology (isch/nonisch) LVEF,, % NYHA VPCs (24h) NSVT (n) Characteristics NYHA II NYHA III NYHA IV Total (n=135) 52.4 ± 11.9 111/23 (82%/17%) 91/43 (68%/32%) 30.1 ± 6.7 2.9 ± 0.8 56 (42%) 55 (40%) 24 (18%) 219 (34-817)* 57 (35%( 35%) * Presented as median with 25th and 75th percentiles

Baseline treatment Diuretics Nitrates Treatment ACE Inhibitors Beta-blockers Digoxin Spironolactone Aspirin Amiodarone Warfarin % 90.3% 89.1% 79.4% 45.1% 68.6% 76.4% 11.1% 14.8% 5.6%

Heart Rate Variability in Heart Failure

HRV measures SDNN, ms SDANN, ms SD, ms RMSDD, ms pnn50,, % TP, ln ms 2 LF, ln ms 2 HF, ln ms 2 LF/HF VLF, ln ms 2 ULF, ln ms 2 Measures Value 107 ± 44.2 90.2 ± 29.1 38.1 ± 18.3 28.9 ± 14.8 3.9 ± 7.4 9.5 ± 2,5 5.9 ± 1.2 5.6 ± 1.4 2.0 ± 1.4 7.9 ± 1.4 9.8 ± 1.6

Changes of Heart Rate and SDNN by NYHA 120 100 80 60 40 75 112 77 106 86 * 69 * HR SDNN 20 0 NYHA II NYHA III NYHA IV *p value < 0.05

Changes of Frequency Domain HRV measures by NYHA 10 9 8 7 6 5 4 3 2 1 0 9,1 5,4 4,8 NYHA II 2,2 9,1 5,2 4,6 NYHA III 2,3 8,3 * * 4,64,5 NYHA IV 1,6 * TP (ln) LF (ln) HF (ln) LF/HF *p value < 0.05

TOTAL MORTALITY

135 patients Follow-up ~2.4 years Non- cardiac 3 pts (5%) 63 patients died 36 pts (57%) PUMP FAILURE DEATH 3 pts (5%) Myocardial Infarction 21 pts (33%) SUDDEN DEATH

Univariable predictors of total mortality among clinical variables Variable RR p 95% CI (cut-off value) NYHA, III-IV IV 3.5 0.003 1.2-4.25 NSVT 1.1 0.04 0.2 3.4 LVEF 30 % 1.5 0.03 0.8 1.7

Univariable predictors of total mortality among HRV measures Variable (cut-off value) RR p 95% CI RR 746 ms 1.5 0.01 0.9-1.9 SDNN < 90 ms 3.0 0.0003 1.3 4.2 SDANN < 70 ms 1.5 0.006 0.9 2.0 TP ln < 9.05 ms 2 1.7 0.002 02 1.1 2.5 LF ln < 5.1 ms 2 1.6 0.005 1.1 2.3 VLF ln < 6.35 ms 2 1.3 0.04 0.9 2.1 ULF ln < 8.1 ms 2 1.2 0.002 0.8 1.6

Multivariable predictors of total mortality Variable (cut-off value) NYHA, III-IV IV Clinical variables RR 2.0 p 0.02 95% CI 1.0-3.3 Variable (cut-off value) SDNN 90 мс HRV measures RR 1.5 p 0.002 02 95% CI 0.6-1.8

Final prognostic multivariable model for total mortality (forward stepwise Cox proportional hazard regression) Variable RR p 95% CI (cut-off value) NYHA, III-IV IV 1.8 0.001 01 0.7-2.8 SDNN 90 ms 1.2 0.002 02 0.2-1.9

Kaplan-Meier Survival by NYHA Cumulative Proportion Surviving (Kaplan-Meier) Complete Censored 1,0 Cumulative Survival Proportion Surviving 0,9 0,8 0,7 0,6 0,5 n=24 n=55 NYHA II NYHA IV NYHA III 0,4 0,3 Log-rank Total mortality 0 5 10 15 20 25 30 35 40 45 50 Months Time p<0.0001 Group 1 Group 2 Group 3

Kaplan-Meier Survival by SDNN Cumulative Proportion Surviving (Kaplan-Meier) Complete Censored 1,0 0,9 SDNN > 110 ms Cumulative Proportion Surviving Survival 0,8 0,7 0,6 0,5 0,4 SDNN 91-109 ms SDNN < 90 ms n=49 n=42 n=37 0,3 0,2 Log rank Total mortality 0 5 10 15 20 25 30 35 40 45 50 Months Time p<0.001 Group 1 Group 2 Group 3

PUMP FAILURE DEATH

Univariable predictors of pump failure death Variable (cut-off value) NYHA, III-IV IV NSVT LVEF 28 % Variable (cut-off value) RR 705 мс (85 ) SDNN 85 ms Clinical variables RR 9.5 1.3 1.6 HRV measures RR 2.3 1.3 p 0.0003 0.003 03 0.02 p 0.0004 004 0.03 95% CI 2.9-16.8 0.3 3.5 0.8 2.4 95% CI 1.2-3.3 0.7 2.2

Multivariable predictors of pump failure death Variable (cut-off value) NYHA, III-IV IV Clinical variables RR 8.1 p 0.001 01 95% CI 2.3-15.7 Variable (cut-off value) RR 705 ms (85 ) HRV measures RR 2.0 p 0.001 001 95% CI 1.1-3.0

Final prognostic multivariable model for pump failure death (forward stepwise Cox proportional hazard regression) Variable (cut-off value) NYHA, III-IV IV RR 8.0 p 0.001 01 95% CI 2.1-14.8 RR 705 ms (85 ) 1.5 0.002 02 0.6 3.8

Kaplan-Meier Survival by NYHA Cumulative Proportion Surviving (Kaplan-Meier) Complete Censored 1,0 NYHA II n=56 Cumulative Survival Proportion Surviving 0,9 0,8 0,7 0,6 n=42 NYHA IV NYHA III n=55 0,5 0,4 Log-rank Pump failure death 0 5 10 15 20 25 30 35 40 45 50 Months Time p<0.05 Group 1 Group 2 Group 3

Kaplan-Meier Survival by mean RR Cumulative Proportion Surviving (Kaplan-Meier) Complete Censored 1,0 Cumulative Proportion Surviving Выживаемость Survival 0,9 0,8 0,7 0,6 0,5 n=89 n=40 RR > 705 ms (<85 bpm ) RR 705 ms ( 85 bpm) 0,4 Log-rank Pump failure death p=0.0004 0,3 0 5 10 15 20 25 30 35 40 45 50 Months Time Group 2, Group 1,

Kaplan-Meier Survival in 2 independent risk factor model n=43 NYHA II + RR mean > 705 ms (<85 bpm ) Survival n=33 NYHA III-IV + RR mean 705 ms ( 85 bpm ) Pump failure death Months

SUDDEN DEATH

Univariable predictors of sudden cardiac death Variable (cut-off value) NYHA, II LVEF 26 % Clinical variables RR 6.5 2.4 p 0.0002 0.004 95% CI 2.4 9.5 1.1 3.6 Variable (cut-off value) LF< < 4.5, ln ms 2 LF/HF < 1.5 HRV measures RR 2.1 3.5 p 0.006 0.001 95% CI 0.9 5.5 1.45 4.49

Multivariable predictors of sudden cardiac death Variable (cut-off value) NYHA, II Clinical variables RR 2.0 p 0.002 02 95% CI 1.0-3.3 LVEF 26 % 1.1 0,04 0.2 4.6

Multivariable predictors of sudden cardiac death HRV measures Variable (cut-off value) RR p 95% CI LF/HF < 1.5 3.5 0.001 1.45 4.49

Final prognostic multivariable model for sudden cardiac death (forward stepwise Cox proportional hazard regression) Variable (cut-off value) NYHA, II RR 3.5 p 0.003 95% CI 2.0 9.5 LVEF 26 % 1.4 0,04 0.4 3.0 LF/HF < 1.5 1.5 0.001 0.5 2.9

1,05 Cumulative Proportion Surviving (Kaplan-Meier) Kaplan-Meier Complete Survival Censored by LF/HF 1.5 1,00 n=68 LF/HF > 1,5 Cumulative Proportion Surviving Survival 0,95 0,90 0,85 n=61 LF/HF 1.5 0,80 0,75 Log-rank Sudden death 0 5 10 15 20 25 30 35 40 45 50 Months Time p=0.001 Group 1, Group 2,

Kaplan-Meier Cumulative Survival Proportion in Surviving 3 independent (Kaplan-Meier) risk factor model Complete Censored 1,0 Cumulative Proportion Surviving Survival 0,9 0,8 0,7 0,6 0,5 0,4 0,3 0,2 0,1 0,0 LVEF<26%+LF/HF<1.5+NYHA II Log-rank LVEF>26% + LF/HF>1.5 + NYHA > II RR= = 9.5 (95% CI 4.4 14.4) 0 5 10 15 20 25 30 35 40 45 50 Months Time p=0,0001 Group 1 Group 2

Conclusions 1. The main HRV indices (both time- and frequency domain) are depressed in heart failure which relates to the severity of heart failure 2. III-IV IV NYHA and SDNN 90 ms are independent predictors of all-cause mortality. 3. III-IV IV NYHA and mean RR 705 ms (HR 85 ) are independent predictors of death from progressive pump failure. Their combination singles out pts at the most increased risk of pump failure death.

Conclusions (continued) 5. Patients in II NYHA, depressed LVEF 26%, and decreased LF/HF 1.5 are independent predictors of sudden death. Their combination singles out patients with heart failure at the most increased risk of sudden death. 6. HRV measures are advantageous over traditional markers of unfavorable prognosis (VPCs( VPCs,, NSVT) in identifying patients with heart failure at increased risk of sudden death.